Adaptimmune : Phase 1 Trial Data On Liver Cancer Show Significant Antitumor Activity

(RTTNews) - Adaptimmune Therapeutics plc (ADAP) provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. The data showed significant antitumor activity with the first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease.

The company reported a complete response in one patient, and tumor reductions with stable disease that has lasted more than 16 weeks in two patients as well as disease control in most patients at the target dose.

Bruno Sangro of Clinica Universidad de Navarra said the first results from the cell therapy trial were of great interest since they indicate obvious antitumor activity in some patients. The treatment has generally been safely applied even to cirrhotic patients.